*Psychiatry and Behavioral Sciences §Oral Medicine, University of Washington †Geriatric Research, Education, and Clinical Center, Puget Sound Veterans Affairs Medical Center ‡Group Health Research Institute, Seattle, WA ∥Kaiser Permanente Division of Research, Oakland, CA.
Clin J Pain. 2014 Feb;30(2):93-101. doi: 10.1097/AJP.0b013e31828e361b.
Chronic opioid therapy (COT) is associated with various adverse outcomes, especially at higher doses, yet little is known about predictors of sustained higher-dose COT. This study aimed to ascertain, among higher-dose COT patients, the association of patient-perceived pros and cons of opioids with continued higher-dose use 1 year later.
Patients (N=1229) in 2 large health plans prescribed ≥50 mg morphine-equivalent dose (MED) per day for chronic noncancer pain completed a survey assessing opioid benefits and harms. The Prescribed Opioid Difficulties Scale questionnaire assessed psychosocial problems, concerns, benefits, and side effects related to opioid use. Logistic regression models estimated the associations of the reported benefits and problems with higher-dose continuation (≥50 mg MED/d) versus dose reduction (<50 mg MED/d) 1 year later.
Over 80% of participants continued higher-dose opioid use at 1 year, regardless of reported problems, concerns, side effects, pain reduction, or perceived helpfulness. Higher scores on the Prescribed Opioid Difficulties Scale Problems subscale (odds ratio=0.79, 95% confidence interval, 0.68-0.92) and Concerns subscale (odds ratio=0.76, 95% confidence interval, 0.65-0.90) were negatively associated with higher-dose use 1 year later. Other baseline measures (opioid helpfulness, reduction in pain, number of side effects, and side effect bothersomeness) were not significantly associated with continued higher-dose use.
The large majority of patients continued using higher-dose opioids regardless of baseline characteristics. These findings suggest the difficulty of reducing opioid dose among chronic higher-dose opioid users.
慢性阿片类药物治疗(COT)与各种不良后果相关,尤其是在较高剂量时,但对于持续使用较高剂量 COT 的预测因素知之甚少。本研究旨在确定在接受较高剂量 COT 的患者中,患者对阿片类药物的利弊的感知与 1 年后继续使用较高剂量之间的关系。
在 2 家大型健康计划中,每天处方≥50 毫克吗啡等效剂量(MED)用于慢性非癌性疼痛的患者完成了一项调查,评估了阿片类药物的益处和危害。处方阿片类药物困难量表问卷评估了与阿片类药物使用相关的心理社会问题、担忧、益处和副作用。逻辑回归模型估计了报告的益处和问题与 1 年后继续使用较高剂量(≥50 mg MED/d)与剂量减少(<50 mg MED/d)之间的关联。
超过 80%的参与者在 1 年内继续使用较高剂量的阿片类药物,无论报告的问题、担忧、副作用、疼痛缓解或感知的益处如何。处方阿片类药物困难量表问题子量表(比值比=0.79,95%置信区间,0.68-0.92)和担忧子量表(比值比=0.76,95%置信区间,0.65-0.90)的评分较高与 1 年后继续使用较高剂量呈负相关。其他基线测量(阿片类药物的帮助程度、疼痛减轻程度、副作用数量和副作用困扰程度)与继续使用较高剂量无显著相关性。
绝大多数患者继续使用较高剂量的阿片类药物,无论基线特征如何。这些发现表明,减少慢性高剂量阿片类药物使用者的阿片类药物剂量具有一定的难度。